rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Qiagen N.V. Common Shares

QGEN · NYSE

Health CareBiotechnologyAbove a falling average

QGEN stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 34 weeks. It is 21.2% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 34
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
16
Institutions holding
320 (-6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

16 disclosed lines: House 16, Senate 0, executive 0; 4 people.

WhoDidAmountTraded
Peter Welch House: U.S. House ClerkVT00sold$1k–$15k24 Mar 2020filed 3 Apr 2020
Peter Welch House: U.S. House ClerkVT00bought$1k–$15k27 Feb 2020filed 10 Mar 2020
Alan S. Lowenthal House: U.S. House ClerkCA47sold$1k–$15k8 Oct 2019filed 8 Nov 2019
Alan S. Lowenthal House: U.S. House ClerkCA47soldspouse$15k–$50k8 Oct 2019filed 8 Nov 2019
Alan S. Lowenthal House: U.S. House ClerkCA47soldspouse$1k8 Oct 2019filed 7 Nov 2019
Alan S. Lowenthal House: U.S. House ClerkCA47boughtspouse$1k–$15k13 Sep 2019filed 21 Sep 2019
Alan S. Lowenthal House: U.S. House ClerkCA47bought$1k–$15k13 Sep 2019filed 21 Sep 2019
Alan S. Lowenthal House: U.S. House ClerkCA47boughtspouse$0k13 Sep 2019filed 21 Sep 2019
Alan S. Lowenthal House: U.S. House ClerkCA47boughtspouse$1k–$15k12 Sep 2019filed 21 Sep 2019
Alan S. Lowenthal House: U.S. House ClerkCA47boughtspouse$0k12 Sep 2019filed 21 Sep 2019
Donna E. Shalala House: U.S. House ClerkFL27sold$1k–$15k23 Jan 2019filed 27 Apr 2020
Donna E. Shalala House: U.S. House ClerkFL27sold$1k–$15k9 Jan 2019filed 27 Apr 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders320-6 on the quarter
New · exited69 · 75
Reported value$5.2B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
WELLINGTON MANAGEMENT GROUP LLPreduced · filed 14 Aug 202612,406,763$484.2M-1,957,540−13.6%
PRINCIPAL FINANCIAL GROUP INCadded · filed 4 Aug 20266,648,681$260.0M+6,643,158+120281.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20266,209,904$240.2M+103,629+1.7%
BlackRock, Inc.added · filed 7 Aug 20265,905,678$230.9M+655,217+12.5%
MORGAN STANLEYadded · filed 13 Aug 20265,042,391$197.2M+851,478+20.3%
EARNEST PARTNERS LLCadded · filed 13 Aug 20264,573,455$178.8M+704,966+18.2%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20264,443,674$173.7M+3,052,347+219.4%
NORGES BANKnew · filed 12 Aug 20264,325,135$168.0M+4,325,135
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20263,845,605$150.4M+3,247,768+543.3%
Amundireduced · filed 11 Aug 20263,683,362$144.0M-1,074,319−22.6%
31 Mar 2023 – 30 Jun 2026
13164314Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Peter Welch HouseVT00 · last 24 Mar 20201 · 1
Alan S. Lowenthal HouseCA47 · last 8 Oct 20196 · 3
Donna E. Shalala HouseFL27 · last 23 Jan 20190 · 2
James B. Renacci HouseOH16 · last 1 Sep 20173 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202562.2%
Operating profit marginFY 2025 · to 31 Dec 202522.3%
Free cash flow marginFY 2025 · to 31 Dec 202521.7%
Return on capital employedFY 2025 · to 31 Dec 20258.1%
Cash conversionFY 2025 · to 31 Dec 2025154%
Debt to equityFY 2025 · to 31 Dec 20250.44×
Revenue growthFY 2024 · to 31 Dec 20240.7%
Earnings per share growthFY 2024 · to 31 Dec 2024-75.0%
Dividend growthFY 2025 · to 31 Dec 20250.0%
Share count trendFY 2024 · to 31 Dec 2024-2.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$839.0M
Free cash flowFY 2025 · to 31 Dec 2025$453.3M

Analyst forecasts

No analyst forecasts yet.